Twist Bioscience Corporation

TWST

NASDAQ

Healthcare

Medical - Diagnostics & Research

South San Francisco, CA, US923 employeestwistbioscience.com

$50.16

+0.63(1.26%)

Mkt Cap $3.1B

$24.16

$54.92

52-Week Range

At a Glance

AI-generated

Revenue breakdown: Ngs Tools (53.6%), Synthetic Genes (29.9%), Antibody Discovery (7.2%).

8-K

Twist Bioscience Corporation entered into Stock Purchase Agreements on February 11, 2026, to issue up to 632,328 shares of common stock: up to 324,558 shares to Invenra Inc. with $5 million cash for a license and technology transfer, and 307,770 shares to two Invenra investors for approximately 6% ownership in Invenra. The company also gained the right to designate one director to the Invenra board and entered Registration Rights Agreements for share resale registration.

$3.1B

Market Cap

$393M

Revenue

-$77M

Net Income

Employees923

Fundamentals

How The Business Makes Money

Revenue by Segment

Ngs Tools53.6%($501M)

Synthetic Genes29.9%($280M)

Antibody Discovery7.2%($67M)

Oligo Pools5.5%($52M)

Dna And Biopharma Libraries3.8%($35M)

Revenue by Geography

Americas61.1%($571M)

EMEA30.8%($288M)

Asia Pacific8.1%($76M)

Activity

What Changed Recently

Securities Issuance

Feb 16, 2026

Unregistered Sales of Equity Securities. The information set forth under Item 8.01 is incorporated into this Item 3.02 by reference. The shares to be issued as

Financial Results

Feb 1, 2026

, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as ame

Financial Results

Jan 11, 2026

, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as ame

Shareholder Vote

Feb 5, 2026

Submission of Matters to a Vote of Security Holders. At the 2026 Annual Meeting of Stockholders of Twist Bioscience Corporation (the "Company"), there were pres

Peer Companies

Company	Price	Change	Market Cap	P/E
EWTXEdgewise Therapeutics, In...	$33.37	+0.69%	$3.6B	-18.3
GPCRStructure Therapeutics In...	$53.27	+6.18%	$3.1B	-20.6
GRDNGuardian Pharmacy Service...	$37.76	+0.37%	$2.4B	47.9
MESOMesoblast Limited	$14.82	-6.20%	$1.9B	-17.9
VRDNViridian Therapeutics, In...	$18.82	-1.70%	$1.6B	-6.8
PRCTPROCEPT BioRobotics Corpo...	$25.14	-0.87%	$1.4B	-15.2
QDELQuidelOrtho Corporation	$17.28	+4.22%	$1.2B	-1.0
QUREuniQure N.V.	$17.15	+1.55%	$1.1B	-4.6

Analyst View

Company Profile

CIK0001581280

ISINUS90184D1000

CUSIP90184D100

Phone800 719 0671

Address681 Gateway Boulevard, South San Francisco, CA, 94080, US

SEC EDGAR